Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04233047|
Expanded Access Status : Available
First Posted : January 18, 2020
Last Update Posted : January 18, 2020
Compassionate use access to fostemsavir (GSK3684934, formerly BMS-663068) for the treatment of HIV infection in individuals with multidrug resistant HIV-1 infection who are experiencing virologic failure and are unable to comprise a suppressive regimen with currently available antiretrovirals.
Direct inquires to the ViiV Compassionate Use Portal via https://viiv-cu-portal.idea-point.com/
|Condition or disease||Intervention/treatment|
|HIV Infections||Drug: Fostemsavir|
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|Official Title:||Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)|
- Drug: Fostemsavir
Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04233047
|Contact: US GSK Clinical Trials Call Center||877-379-3718||GSKClinicalSupportHD@gsk.com|
|Contact: EU GSK Clinical Trials Call Center||GSKClinicalSupportHD@gsk.com|
|Study Director:||GSK Clinical Trials||ViiV Healthcare|